FLT3 and acute myeloid leukemia: In our study on FLT3-mutated AML, the median age in the posaconazole group (53.5 years) was similar to that reported by Cornely et al.9 in unselected patients affected by AML who demonstrated a IFD proven/probable IFD incidence of 2% in the posaconazole arm.